GAGE5 Inhibitors
GAGE5 inhibitors encompass a range of compounds that exert their effects through distinct biochemical mechanisms, ultimately leading to the decreased functional activity of GAGE5. One class of inhibitors targets intracellular signaling cascades, such as the MAPK/ERK and PI3K/Akt pathways, which are crucial for the regulation of various cellular processes, including those that may govern the functional activity of GAGE5. By impeding these pathways at critical junctures, such as MEK1/2 or PI3K, these inhibitors indirectly lead to the downregulation of GAGE5 activity. Moreover, the inhibition of protein kinase C and Aurora kinase impacts cell cycle progression and intracellular signaling, respectively, which could result in attenuated GAGE5 activity given it is functionally intertwined with these processes.
Another approach to inhibiting GAGE5 involves the disruption of protein stability and synthesis. Proteasome inhibitors, for instance, prevent the degradation of proteins, potentially causing an accumulation of regulatory proteins that suppress GAGE5 activity. Similarly, inhibitors of molecular chaperones like HSP90 may destabilize client proteins, including possibly GAGE5, thereby reducing its function. The inhibition of mTOR, a central regulator of cell growth and protein synthesis, is another strategy that could impinge upon the pathways regulating GAGE5, resulting in lower activity levels.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A potent protein kinase inhibitor that interferes with the phosphorylation events necessary for the activation of many proteins, including GAGE5. By blocking kinase activity, staurosporine can reduce the functional activity of GAGE5. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A specific inhibitor of phosphoinositide 3-kinases (PI3K), leading to the blockade of the Akt signaling pathway. Since GAGE5 may be regulated by PI3K/Akt pathway, LY294002's action would result in the inhibition of GAGE5 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that blocks the mTORC1 complex, which is a downstream component of the PI3K/Akt pathway. This inhibition can decrease the activity of proteins regulated by this pathway, including GAGE5. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An inhibitor of mitogen-activated protein kinase kinase (MEK), which is part of the MAPK/ERK pathway. Inhibition of this pathway may lead to decreased activation of proteins like GAGE5 that are downstream targets. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A selective inhibitor of p38 MAPK, this compound would hinder the p38 MAPK signaling cascade, diminishing the activity of proteins such as GAGE5 that might be influenced by this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), disrupting the JNK signaling pathway. Proteins whose activity is modulated by JNK signaling, such as GAGE5, would experience reduced functional activity due to this inhibition. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
A selective inhibitor of the Rho-associated protein kinase (ROCK), which could lead to changes in cytoskeletal dynamics and cell motility. Given GAGE5's function is related to these cellular processes, its activity would be inhibited by Y-27632. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
An epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that impedes EGFR signaling. Given GAGE5 is regulated by or associated with the EGFR pathway, the inhibition of EGFR would result in decreased GAGE5 activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A potent and irreversible PI3K inhibitor, which would suppress the PI3K/Akt pathway. This suppression could lead to a reduction in the activity of downstream proteins such as GAGE5 that are regulated by this pathway. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
An inhibitor of histone deacetylases (HDAC), which affects chromatin structure and gene expression. Assuming the expression or activity of GAGE5 is influenced by HDAC activity, TSA would lead to the inhibition of GAGE5. | ||||||